A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
for Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Drug: Nadofaragene Firadenovec
38 locations incl. Tucson
Sponsor: Ferring Pharmaceuticals
Sex: All·Age: 18+
Code: NCT06545955·Phase 3·Recruiting